RxDoctor Payments Data

Tena Payton-Vance

Family · Romulus, MINPI 1700371085

Payments from drug & device makers

$1,826in general payments, 2019–2025

Across 92 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$306
  • Otsuka America Pharmaceutical, Inc.$294
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$250
  • Indivior Inc.$229
  • Teva Pharmaceuticals USA, Inc.$185
  • Alkermes, Inc.$163
  • plus $399 from 6 others

What the payments were for

  • Food & beverage$1,72995%
  • Education$975%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,826 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$19,413
Medicare patients
44
Services billed
171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole51$75,814
Abilify MaintenaAripiprazole23$65,986
VraylarCariprazine Hcl40$58,207
Invega SustennaPaliperidone Palmitate14$34,485
TrintellixVortioxetine Hydrobromide49$24,657
Lurasidone Hcl49$18,882
Fluphenazine Hcl31$5,956
Aripiprazole144$3,912
Haloperidol65$2,670
Paliperidone ErPaliperidone14$2,474
Divalproex Sodium ErDivalproex Sodium41$2,474
Quetiapine Fumarate190$2,294
Olanzapine86$1,603
Trazodone Hcl166$1,438
Asenapine Maleate13$1,379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$294$141,80174 claims
AbbVieVraylar$306$58,20740 claims
Johnson & JohnsonInvega Sustenna$145$34,48514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.

Other family in Romulus

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →